Immunocore Holdings PLC IMCR.OQ IMCR.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Abingdon Oxfordshire-based company is expected to report a 25.8% increase in revenue to $94.772 million from $75.35 million a year ago, according to the mean estimate from 15 analysts, based on LSEG data.
LSEG's mean analyst estimate for Immunocore Holdings PLC is for a loss of 21 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Immunocore Holdings PLC is $66.00, about 50.7% above its last closing price of $32.53
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.37
-0.39
0.10
Beat
125.7
Dec. 31 2025
-0.29
-0.26
-0.47
Missed
-83
Sep. 30 2024
-0.35
-0.35
0.17
Beat
148.4
Jun. 30 2024
-0.55
-0.48
-0.23
Beat
51.7
Mar. 31 2024
-0.38
-0.36
-0.49
Missed
-35.4
Dec. 31 2023
-0.28
-0.28
-0.40
Missed
-47
Sep. 30 2023
-0.35
-0.35
0.05
Beat
113.8
Jun. 30 2023
-0.40
-0.41
-0.36
Beat
9.7
This summary was machine generated August 5 at 09:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)